Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats

Establishment of a Patient-Derived Tumor Xenograft Model and Application for Precision Cancer Medicine

(2018) Seiji Okada et al.   CHEMICAL & PHARMACEUTICAL BULLETIN

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2

(2018) Mark C. de Gooijer et al.   NEOPLASIA

Obstacles to Brain Tumor Therapy: Key ABC Transporters

(2017) Juwina Wijaya et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Effects of raloxifene against letrozole-induced bone loss in chemically-induced model of menopause in mice

(2017) Abul Kalam et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014

(2017) Quinn T Ostrom et al.   NEURO-ONCOLOGY

Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells

(2017) Amanda Tivnan et al.   Oncotarget

Humanized Mouse Xenograft Models: Narrowing the Tumor–Microenvironment Gap

(2016) J. Jason Morton et al.   CANCER RESEARCH

Effective treatment of glioblastoma requires crossing the blood–brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine

(2015) Sang-Soo Kim et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells

(2015) Jessian L. Munoz et al.   CANCER LETTERS

Bevacizumab in recurrent glioblastoma: open issues

(2015) Enrico Franceschi et al.   Future Oncology

Preclinical Pharmacological Evaluation of Letrozole as a Novel Treatment for Gliomas

(2015) N. Dave et al.   MOLECULAR CANCER THERAPEUTICS

Aromatase and estrogen receptor alpha mRNA expression as prognostic biomarkers in patients with astrocytomas

(2014) J. M. Dueñas Jiménez et al.   JOURNAL OF NEURO-ONCOLOGY

The pharmacokinetics of letrozole in brain and brain tumor in rats with orthotopically implanted C6 glioma, assessed using intracerebral microdialysis

(2013) Nimita Dave et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Humanized NOD-SCID IL2rg –/– mice as a preclinical model for cancer research and its potential use for individualized cancer therapies

(2013) Qianjun Zhou et al.   CANCER LETTERS

Investigation of the effect of active efflux at the blood–brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system

(2013) Mari Miyajima et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

17-β-Estradiol: A Powerful Modulator of Blood–Brain Barrier BCRP Activity

(2010) Anika MS Hartz et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

BCRP at the Blood−Brain Barrier: Genomic Regulation by 17β-Estradiol

(2010) Anne Mahringer et al.   MOLECULAR PHARMACEUTICS

Regulation of P-glycoprotein and other ABC drug transporters at the blood–brain barrier

(2010) David S. Miller   TRENDS IN PHARMACOLOGICAL SCIENCES

The Neuropharmacokinetics of Temozolomide in Patients with Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation

(2009) J. Portnow et al.   CLINICAL CANCER RESEARCH

Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes

(2009) K. Murai et al.   XENOBIOTICA

A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients

(2008) M. Schaich et al.   ANNALS OF ONCOLOGY